136 related articles for article (PubMed ID: 10187778)
21. A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease.
Hou Y; McInnes B; Hinek A; Karpati G; Mahuran D
J Biol Chem; 1998 Aug; 273(33):21386-92. PubMed ID: 9694901
[TBL] [Abstract][Full Text] [Related]
22. [Isolation and characteristics of hexosaminidase A and activator protein from human kidney].
Aronovich EL; Akhunov VS; Krasnopol'skaia KD
Biokhimiia; 1990 Jan; 55(1):43-51. PubMed ID: 2140519
[TBL] [Abstract][Full Text] [Related]
23. Gangliosides GM2, IV4GalNAcGM1b, and IV4GalNAcGC1a as antigens for monoclonal immunoglobulin M in neuropathy associated with gammopathy.
Ilyas AA; Li SC; Chou DK; Li YT; Jungalwala FB; Dalakas MC; Quarles RH
J Biol Chem; 1988 Mar; 263(9):4369-73. PubMed ID: 2450092
[TBL] [Abstract][Full Text] [Related]
24. Interaction of the GM2-activator protein with phospholipid-ganglioside bilayer membranes and with monolayers at the air-water interface.
Giehl A; Lemm T; Bartelsen O; Sandhoff K; Blume A
Eur J Biochem; 1999 May; 261(3):650-8. PubMed ID: 10215880
[TBL] [Abstract][Full Text] [Related]
25. Procedure for separation of GM2 ganglioside species with different ceramide structures by a flash reversed-phase silica gel liquid chromatography.
Mauri L; Valsecchi M; Casellato R; Li SC; Li YT; Sonnino S
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Oct; 796(1):1-10. PubMed ID: 14552811
[TBL] [Abstract][Full Text] [Related]
26. Ganglioside GM2: a potential biomarker for cholangiocarcinoma.
Talabnin K; Talabnin C; Kumagai T; Sutatum N; Khiaowichit J; Dechsukhum C; Ishihara M; Azadi P; Sripa B
J Int Med Res; 2020 Jul; 48(7):300060520903216. PubMed ID: 32692591
[TBL] [Abstract][Full Text] [Related]
27. Degradation of membrane-bound ganglioside GM2 by beta -hexosaminidase A. Stimulation by GM2 activator protein and lysosomal lipids.
Werth N; Schuette CG; Wilkening G; Lemm T; Sandhoff K
J Biol Chem; 2001 Apr; 276(16):12685-90. PubMed ID: 11278374
[TBL] [Abstract][Full Text] [Related]
28. Sialidase-mediated depletion of GM2 ganglioside in Tay-Sachs neuroglia cells.
Igdoura SA; Mertineit C; Trasler JM; Gravel RA
Hum Mol Genet; 1999 Jun; 8(6):1111-6. PubMed ID: 10332044
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and enzymatic susceptibility of a series of novel GM2 analogs.
Fuse T; Ando H; Imamura A; Sawada N; Ishida H; Kiso M; Ando T; Li SC; Li YT
Glycoconj J; 2006 Jul; 23(5-6):329-43. PubMed ID: 16897176
[TBL] [Abstract][Full Text] [Related]
30. A novel heptasialosyl c-series ganglioside in embryonic chicken brain: its structure and stage-specific expression.
Saito M; Kitamura H; Sugiyama K
Biochim Biophys Acta; 2002 May; 1571(1):18-26. PubMed ID: 12031286
[TBL] [Abstract][Full Text] [Related]
31. Classification of disorders of GM2 ganglioside hydrolysis using 3H-GM2 as substrate.
Novak A; Callahan JW; Lowden JA
Biochim Biophys Acta; 1994 Mar; 1199(2):215-23. PubMed ID: 8123671
[TBL] [Abstract][Full Text] [Related]
32. Deficiency of the hexosaminidase A activator protein in a case of GM2 gangliosidosis; variant AB.
Hechtman P; Gordon BA; Ng Ying Kin NM
Pediatr Res; 1982 Mar; 16(3):217-22. PubMed ID: 6801612
[TBL] [Abstract][Full Text] [Related]
33. The protein activator specific for the enzymic hydrolysis of GM2 ganglioside in normal human brain and brains of three types of GM2 gangliosidosis.
Hirabayashi Y; Li YT; Li SC
J Neurochem; 1983 Jan; 40(1):168-75. PubMed ID: 6848657
[TBL] [Abstract][Full Text] [Related]
34. The degradative pathway of gangliosides GM1 and GM2 in Neuro2a cells by sialidase.
Riboni L; Caminiti A; Bassi R; Tettamanti G
J Neurochem; 1995 Jan; 64(1):451-4. PubMed ID: 7798945
[TBL] [Abstract][Full Text] [Related]
35. Formation of a ternary complex between GM2 activator protein, GM2 ganglioside and hexosaminidase A.
Yadao F; Hechtman P; Kaplan F
Biochim Biophys Acta; 1997 Jun; 1340(1):45-52. PubMed ID: 9217013
[TBL] [Abstract][Full Text] [Related]
36. Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease.
Seyrantepe V; Demir SA; Timur ZK; Von Gerichten J; Marsching C; Erdemli E; Oztas E; Takahashi K; Yamaguchi K; Ates N; Dönmez Demir B; Dalkara T; Erich K; Hopf C; Sandhoff R; Miyagi T
Exp Neurol; 2018 Jan; 299(Pt A):26-41. PubMed ID: 28974375
[TBL] [Abstract][Full Text] [Related]
37. Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosa.
Dohi T; Ohta S; Hanai N; Yamaguchi K; Oshima M
J Biol Chem; 1990 May; 265(14):7880-5. PubMed ID: 2139874
[TBL] [Abstract][Full Text] [Related]
38. Glycosphingolipids in Bomirski transplantable melanomas in hamsters.
Ren SL; Slominski A; Yu RK
Cancer Res; 1989 Dec; 49(24 Pt 1):7051-6. PubMed ID: 2582447
[TBL] [Abstract][Full Text] [Related]
39. Precursor-product relationship between GM1 and GD1a biosynthesized from exogenous GM2 ganglioside in rat liver.
Trinchera M; Ghidoni R
J Biochem; 1990 Apr; 107(4):619-23. PubMed ID: 2358435
[TBL] [Abstract][Full Text] [Related]
40. Biochemical and molecular aspects of late-onset GM2-gangliosidosis: B1 variant as a prototype.
Suzuki K; Vanier MT
Dev Neurosci; 1991; 13(4-5):288-94. PubMed ID: 1840099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
